A postmarketing evaluation of the frequency of use and safety of live attenuated influenza vaccine use in nonrecommended children younger than 5 years
- Tennis, Patricia
- Toback, Seth L.
- Andrews, Elizabeth
- McQuay, Lisa J.
- Ambrose, Christopher S.
DOIAbstract
AbstractThe 2007 US approval for use of live attenuated influenza vaccine (LAIV) in children aged 24–59 months included precautions against use in (1) children <24 months and children aged 24–59 months with (2) asthma, (3) recurrent wheezing, and (4) altered immunocompetence. A postmarketing commitment was initiated to monitor LAIV use and the frequency of select safety outcomes in these cohorts. Vaccination rates and the frequency of hospitalizations or emergency department visits within 42 days after LAIV and trivalent inactivated influenza vaccine (TIV) administration were estimated from 2007 to 2009 claims data from a health insurance database. Rates of LAIV use per 10,000 child-days among cohorts 1, 2, and 4 were low relative to rates ...
Add to ORKG